UnitedHealthcare Medicare Advantage Plan granted prior authorization for Lifeward’s ReWalk 7 Personal Exoskeleton on November 17 2025, expanding coverage for the device under Medicare Advantage plans.
The approval opens a significant payer channel that is expected to accelerate sales and improve cash‑flow predictability for Lifeward. It follows Medicare’s April 2024 reimbursement pathway and a June 2025 administrative law judge ruling that the ReWalk is “reasonable and necessary” for beneficiaries, positioning the company to capture a growing Medicare market.
Lifeward’s Q3 2025 earnings report showed revenue of $6.2 million, a 1.1 % year‑over‑year increase, and a non‑GAAP operating loss of $3.0 million. Revenue from traditional products and services, which includes the ReWalk, totaled $3.1 million, while AlterG products and services generated an equal $3.1 million. The modest revenue growth was driven by Medicare‑related sales, which accounted for a 24 % year‑over‑year increase in the traditional segment.
The company’s gross profit reached $2.7 million, or 43.7 % of revenue, up from 36.2 % in the prior year, reflecting improved pricing and cost control. The operating loss narrowed compared with the prior quarter, largely due to disciplined expense management amid modest revenue growth.
Mark Grant, Lifeward’s CEO, said the UnitedHealthcare approval signals a significant advancement in payer adoption and underscores the company’s progress toward scalable, sustainable growth in the U.S. market. He also noted steady progress across commercial execution, operations, and patient access during the quarter.
Investors reacted negatively to the Q3 earnings miss, as revenue fell short of the consensus estimate of $6.44 million, while the non‑GAAP EPS of –$0.20 beat the expected –$0.22. The approval is expected to support long‑term growth, but the company remains focused on reducing operating losses and achieving profitability.
Lifeward reaffirmed its full‑year 2025 guidance of $24 million to $26 million in revenue and a net loss of $12 million to $14 million, signaling confidence in the Medicare channel while acknowledging ongoing cash burn and the need for continued cost discipline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.